Cargando…
Current Status and Prospects of Clinical Treatment of Osteosarcoma
Osteosarcoma, one of the common malignant tumors in the skeletal system, originates in mesenchymal tissue, and the most susceptible area of occurrence is the metaphysis with its abundant blood supply. Tumors are characterized by highly malignant spindle stromal cells that can produce bone-like tissu...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500272/ https://www.ncbi.nlm.nih.gov/pubmed/36128851 http://dx.doi.org/10.1177/15330338221124696 |
_version_ | 1784795181920288768 |
---|---|
author | Jiang, Zong-Yuan Liu, Ji-Bin Wang, Xiao-Feng Ma, Yu-Shui Fu, Da |
author_facet | Jiang, Zong-Yuan Liu, Ji-Bin Wang, Xiao-Feng Ma, Yu-Shui Fu, Da |
author_sort | Jiang, Zong-Yuan |
collection | PubMed |
description | Osteosarcoma, one of the common malignant tumors in the skeletal system, originates in mesenchymal tissue, and the most susceptible area of occurrence is the metaphysis with its abundant blood supply. Tumors are characterized by highly malignant spindle stromal cells that can produce bone-like tissue. Most of the osteosarcoma are primary, and a few are secondary. Osteosarcoma occurs primarily in children and adolescents undergoing vigorous bone growth and development. Most cases involve rapid tumor development and early blood metastasis. In recent years, research has grown in the areas of molecular biology, imaging medicine, biological materials, applied anatomy, surgical techniques, biomechanics, and comprehensive treatment of tumors. With developments in molecular biology and tissue bioengineering, treatment methods have also made great progress, especially in comprehensive limb salvage treatment, which significantly enhances the quality of life after surgery and improves the 5-year survival rate of patients with malignant tumors. This article provides a review of limb salvage, immunotherapy, gene therapy, and targeted therapy from traditional amputation to neoadjuvant chemotherapy, providing a reference for current clinical treatments for osteosarcoma. |
format | Online Article Text |
id | pubmed-9500272 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-95002722022-09-24 Current Status and Prospects of Clinical Treatment of Osteosarcoma Jiang, Zong-Yuan Liu, Ji-Bin Wang, Xiao-Feng Ma, Yu-Shui Fu, Da Technol Cancer Res Treat Review Osteosarcoma, one of the common malignant tumors in the skeletal system, originates in mesenchymal tissue, and the most susceptible area of occurrence is the metaphysis with its abundant blood supply. Tumors are characterized by highly malignant spindle stromal cells that can produce bone-like tissue. Most of the osteosarcoma are primary, and a few are secondary. Osteosarcoma occurs primarily in children and adolescents undergoing vigorous bone growth and development. Most cases involve rapid tumor development and early blood metastasis. In recent years, research has grown in the areas of molecular biology, imaging medicine, biological materials, applied anatomy, surgical techniques, biomechanics, and comprehensive treatment of tumors. With developments in molecular biology and tissue bioengineering, treatment methods have also made great progress, especially in comprehensive limb salvage treatment, which significantly enhances the quality of life after surgery and improves the 5-year survival rate of patients with malignant tumors. This article provides a review of limb salvage, immunotherapy, gene therapy, and targeted therapy from traditional amputation to neoadjuvant chemotherapy, providing a reference for current clinical treatments for osteosarcoma. SAGE Publications 2022-09-21 /pmc/articles/PMC9500272/ /pubmed/36128851 http://dx.doi.org/10.1177/15330338221124696 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Jiang, Zong-Yuan Liu, Ji-Bin Wang, Xiao-Feng Ma, Yu-Shui Fu, Da Current Status and Prospects of Clinical Treatment of Osteosarcoma |
title | Current Status and Prospects of Clinical Treatment of Osteosarcoma |
title_full | Current Status and Prospects of Clinical Treatment of Osteosarcoma |
title_fullStr | Current Status and Prospects of Clinical Treatment of Osteosarcoma |
title_full_unstemmed | Current Status and Prospects of Clinical Treatment of Osteosarcoma |
title_short | Current Status and Prospects of Clinical Treatment of Osteosarcoma |
title_sort | current status and prospects of clinical treatment of osteosarcoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500272/ https://www.ncbi.nlm.nih.gov/pubmed/36128851 http://dx.doi.org/10.1177/15330338221124696 |
work_keys_str_mv | AT jiangzongyuan currentstatusandprospectsofclinicaltreatmentofosteosarcoma AT liujibin currentstatusandprospectsofclinicaltreatmentofosteosarcoma AT wangxiaofeng currentstatusandprospectsofclinicaltreatmentofosteosarcoma AT mayushui currentstatusandprospectsofclinicaltreatmentofosteosarcoma AT fuda currentstatusandprospectsofclinicaltreatmentofosteosarcoma |